Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory P Forlenza

Showing results (81-90 of 146) with videos related to

Pageof 15
Sort By:
Diabetes Technology & Therapeutics|July 20, 2023
Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to PolicymakingGrazia Aleppo, Irl B Hirsch, Christopher G Parkin, et al.
The New England Journal of Medicine|March 15, 2023
Trial of Hybrid Closed-Loop Control in Young Children with Type 1 DiabetesR Paul Wadwa, Zachariah W Reed, Bruce A Buckingham, et al.
Journal of Diabetes Science and Technology|April 27, 2022
Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop TrialLaya Ekhlaspour, Dan Raghinaru, Gregory P Forlenza, et al.
Pediatric Diabetes|January 10, 2022
Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trialGregory P Forlenza, Laya Ekhlaspour, Linda A DiMeglio, et al.
Journal of Diabetes Science and Technology|December 16, 2022
Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility CriteriaRodolfo J Galindo, Grazia Aleppo, Christopher G Parkin, et al.
Diabetes Technology & Therapeutics|February 20, 2024
Real-World Evidence of Omnipod<sup>®</sup> 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 DiabetesGregory P Forlenza, Daniel J DeSalvo, Grazia Aleppo, et al.
Diabetes Technology & Therapeutics|May 27, 2016
Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 DiabetesAndrew W Karlin, Trang T Ly, Laura Pyle, et al.
Diabetes Technology & Therapeutics|August 3, 2018
Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 DiabetesBruce A Buckingham, Mark P Christiansen, Gregory P Forlenza, et al.
Diabetes Technology & Therapeutics|March 30, 2019
Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 DiabetesGregory P Forlenza, Bruce A Buckingham, Mark P Christiansen, et al.
Diabetes Technology & Therapeutics|November 23, 2020
Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and PreschoolersLaya Ekhlaspour, Melissa J Schoelwer, Gregory P Forlenza, et al.
Pageof 15

Showing results (81-90 of 146) with videos related to

Sort By:
Pageof 15
Diabetes Technology & Therapeutics|July 20, 2023
Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to PolicymakingGrazia Aleppo, Irl B Hirsch, Christopher G Parkin, et al.
The New England Journal of Medicine|March 15, 2023
Trial of Hybrid Closed-Loop Control in Young Children with Type 1 DiabetesR Paul Wadwa, Zachariah W Reed, Bruce A Buckingham, et al.
Journal of Diabetes Science and Technology|April 27, 2022
Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop TrialLaya Ekhlaspour, Dan Raghinaru, Gregory P Forlenza, et al.
Pediatric Diabetes|January 10, 2022
Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trialGregory P Forlenza, Laya Ekhlaspour, Linda A DiMeglio, et al.
Journal of Diabetes Science and Technology|December 16, 2022
Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility CriteriaRodolfo J Galindo, Grazia Aleppo, Christopher G Parkin, et al.
Diabetes Technology & Therapeutics|February 20, 2024
Real-World Evidence of Omnipod<sup>®</sup> 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 DiabetesGregory P Forlenza, Daniel J DeSalvo, Grazia Aleppo, et al.
Diabetes Technology & Therapeutics|May 27, 2016
Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 DiabetesAndrew W Karlin, Trang T Ly, Laura Pyle, et al.
Diabetes Technology & Therapeutics|August 3, 2018
Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 DiabetesBruce A Buckingham, Mark P Christiansen, Gregory P Forlenza, et al.
Diabetes Technology & Therapeutics|March 30, 2019
Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 DiabetesGregory P Forlenza, Bruce A Buckingham, Mark P Christiansen, et al.
Diabetes Technology & Therapeutics|November 23, 2020
Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and PreschoolersLaya Ekhlaspour, Melissa J Schoelwer, Gregory P Forlenza, et al.
Pageof 15